Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05490472 · ClinicalTrials.gov registry record · Phase 1
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
A Phase 1 study of Solid Tumors and Triple Negative Breast Cancer (TNBC), sponsored by Jacobio Pharmaceuticals Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 102
- Enrollment target
- 8
- Study locations
NCT05490472: Recruiting Phase 1 study of Solid Tumors and Triple Negative Breast Cancer (TNBC), sponsored by Jacobio Pharmaceuticals Co..
NCT05490472 is a Phase 1 study of Solid Tumors and Triple Negative Breast Cancer (TNBC) that is actively recruiting participants, run by Jacobio Pharmaceuticals Co.. The registered enrollment target is 102 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (64% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05490472, a Phase 1 study of Solid Tumors and Triple Negative Breast Cancer (TNBC), is actively recruiting participants, sponsored by Jacobio Pharmaceuticals Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 102 participants
- Enrollment target
- 8
- Study locations
Study Summary
This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors.
Primary Outcome
A DLT is defined as an adverse event (AE) regardless of attribution unless clearly related to underlying disease or extraneous cause during the first 21 days of Cycle 1 (DLT observation period).
Conditions Studied
Interventions
- DRUG JAB-2485 (Aurora A inhibitor)
Study Locations (8)
Beijing Municipality
- Cancer Hospital Chinese Academy of Medical Sciences - Beijing
- Peking University Third Hospital - Beijing
Michigan
- Henry Ford Health System - Detroit
Missouri
- Washington University - St Louis
Texas
- Mary Crowley Cancer Research - Dallas
Utah
- University of Utah Huntsman Cancer Institute - Salt Lake City
Jilin
- Jilin Cancer Hospital - Changchun
Shandong
- Shandong Cancer Hospital - Jinan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2022-12-20 |
| Est. Completion | 2027-08 |
| Phase | Phase 1 |
What NCT05490472 shows while recruiting
NCT05490472 is an interventional study that assigns participants to a tested intervention. The registered 102 participants enrollment target is mid-sized for trials with a published cap, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (64% lower).
The record links to 5 conditions, with Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which JAB-2485 (Aurora A inhibitor) is the first listed.
NCT05490472 lists 8 locations in 7 states (Beijing Municipality, Michigan, Missouri).
Frequently Asked Questions
What is clinical trial NCT05490472 about?
NCT05490472 is a clinical study titled "JAB-2485 Activity in Adult Patients With Advanced Solid Tumors". This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors.
What is the current status of trial NCT05490472?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 102 participants. The study started on 2022-12-20. Estimated completion is 2027-08.
What conditions does trial NCT05490472 study?
This clinical trial studies the following conditions: Solid Tumors, Triple Negative Breast Cancer (TNBC), Small Cell Lung Cancer (SCLC), ER+ Breast Cancer, ARID1A Gene Mutation.
What interventions are being tested in trial NCT05490472?
The interventions under investigation include: JAB-2485 (Aurora A inhibitor) (DRUG).
Who is sponsoring clinical trial NCT05490472?
This trial is sponsored by Jacobio Pharmaceuticals Co., which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05490472 being conducted?
This trial has 8 study locations across Michigan, Missouri, Texas, Utah, Beijing Municipality. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05490472's enrollment target sits among peer trials
102 53rd of 125 higher than 73 of 125 other Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RECRUITING · Phase 1
-
Study of AUBE00 in Patients With Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03704662 · 102 participants · NA
Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
- NCT04174742 · 102 participants
Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer
- NCT04275362 · 102 participants
Gait Analysis of a Lateral-Pivot Design Total Knee Replacement
- NCT04541082 · 102 participants · Phase 1
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI